HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

John B Buse Selected Research

Biomarkers (Surrogate Marker)

7/2012Effects of sensor-augmented pump therapy on glycemic variability in well-controlled type 1 diabetes in the STAR 3 study.
1/2008Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.
1/2007Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


John B Buse Research Topics

Disease

159Type 2 Diabetes Mellitus (MODY)
11/2022 - 07/2002
40Hypoglycemia (Reactive Hypoglycemia)
11/2021 - 07/2009
34Cardiovascular Diseases (Cardiovascular Disease)
11/2022 - 06/2008
29Stroke (Strokes)
11/2021 - 11/2002
28Type 1 Diabetes Mellitus (Autoimmune Diabetes)
01/2022 - 07/2010
27Myocardial Infarction
11/2021 - 11/2002
21Heart Failure
11/2022 - 08/2003
19Hyperglycemia
12/2021 - 01/2002
19Body Weight (Weight, Body)
04/2021 - 01/2007
14Weight Loss (Weight Reduction)
12/2020 - 11/2004
11Chronic Renal Insufficiency
11/2022 - 11/2018
10Nausea
12/2019 - 07/2009
9Neoplasms (Cancer)
10/2020 - 07/2011
8Diabetic Ketoacidosis (Ketoacidosis, Diabetic)
01/2022 - 09/2015
8Dyslipidemias (Dyslipidemia)
01/2020 - 07/2002
8Weight Gain
01/2019 - 06/2009
7Pancreatitis
01/2018 - 07/2011
6COVID-19
11/2022 - 01/2021
6Diabetes Mellitus
11/2020 - 02/2003
6Insulin Resistance
01/2018 - 06/2003
5Ketosis
01/2022 - 09/2015
5Obesity
01/2020 - 03/2005
5Acute Coronary Syndrome
01/2020 - 09/2013
5Unstable Angina
12/2019 - 04/2010
4Peripheral Arterial Disease
10/2021 - 01/2018
4Infections
10/2021 - 09/2018
4Pancreatic Neoplasms (Pancreatic Cancer)
01/2020 - 04/2016
4Vomiting
09/2015 - 01/2011
4Inflammation (Inflammations)
09/2013 - 06/2011
3Hypertension (High Blood Pressure)
01/2021 - 02/2013
3Diabetes Complications
10/2019 - 06/2018
3Diarrhea
09/2018 - 01/2011
3Glucose Intolerance
04/2010 - 01/2002
2Kidney Diseases (Kidney Disease)
11/2022 - 01/2018
2Albuminuria
01/2022 - 01/2021
2Vascular Diseases (Vascular Disease)
11/2020 - 01/2016
2Overweight
01/2020 - 03/2016
2Chronic Kidney Failure (Chronic Renal Failure)
01/2020 - 01/2017
2Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
11/2019 - 01/2019

Drug/Important Bio-Agent (IBA)

71Insulin (Novolin)FDA Link
01/2022 - 06/2003
58Glucose (Dextrose)FDA LinkGeneric
11/2022 - 01/2002
38LiraglutideFDA Link
01/2022 - 07/2009
24Insulin Glargine (Lantus)FDA Link
11/2021 - 06/2009
22Exenatide (Byetta)FDA Link
01/2020 - 07/2003
19Metformin (Glucophage)FDA LinkGeneric
04/2021 - 01/2004
18LipidsIBA
01/2020 - 01/2004
16Blood Glucose (Blood Sugar)IBA
11/2022 - 07/2015
16Glucagon-Like Peptide-1 Receptor AgonistsIBA
01/2022 - 01/2013
15insulin degludecIBA
11/2021 - 11/2014
15Glucagon-Like Peptide-1 ReceptorIBA
04/2021 - 07/2009
15Glucagon-Like Peptide 1 (GLP 1)IBA
12/2020 - 10/2008
15Hypoglycemic Agents (Hypoglycemics)IBA
01/2020 - 07/2003
14omega-Chloroacetophenone (Mace)IBA
11/2021 - 07/2011
13Sodium-Glucose Transporter 2 InhibitorsIBA
11/2022 - 07/2015
12semaglutideIBA
01/2022 - 01/2019
12Sitagliptin Phosphate (Januvia)FDA Link
04/2021 - 07/2015
12Pharmaceutical PreparationsIBA
01/2021 - 08/2005
12Glycated Hemoglobin (Glycosylated Hemoglobin)IBA
01/2020 - 01/2007
11Sodium-Glucose Transport ProteinsIBA
01/2021 - 07/2015
8Dipeptidyl-Peptidase IV InhibitorsIBA
01/2021 - 07/2015
8IncretinsIBA
01/2018 - 11/2004
7SodiumIBA
11/2022 - 11/2018
7Hemoglobins (Hemoglobin)IBA
11/2021 - 05/2009
7Pioglitazone (Actos)FDA Link
01/2019 - 01/2004
6CreatinineIBA
01/2021 - 01/2017
6(2S,3R,4R,5S,6R)- 2- (4- chloro- 3- (4- ethoxybenzyl)phenyl)- 6- (methylthio)tetrahydro- 2H- pyran- 3,4,5- triolIBA
01/2021 - 07/2015
6Fenofibrate (CiL)FDA LinkGeneric
01/2020 - 04/2010
6Triglycerides (Triacylglycerol)IBA
01/2017 - 07/2002
5ThiazolidinedionesIBA
11/2020 - 08/2003
5Peroxisome Proliferator-Activated Receptors (PPAR)IBA
01/2020 - 08/2005
5Fibric Acids (Fibrates)IBA
01/2020 - 06/2007
5HDL CholesterolIBA
01/2017 - 07/2002
52,4-thiazolidinedione (thiazolidinedione)IBA
07/2011 - 01/2004
4KetonesIBA
01/2021 - 09/2015
4LDL CholesterolIBA
01/2020 - 11/2007
4Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
01/2020 - 06/2007
4aleglitazarIBA
01/2018 - 09/2013
4Insulin Lispro (Humalog)FDA Link
07/2011 - 05/2009
4Rosiglitazone (Avandia)FDA Link
07/2009 - 01/2004
3TTP399IBA
01/2022 - 01/2019
3GlucokinaseIBA
01/2022 - 01/2019
3Peptides (Polypeptides)IBA
04/2021 - 09/2009
3SymportersIBA
11/2020 - 11/2018
3AlbuminsIBA
01/2020 - 01/2020
3Nonesterified Fatty Acids (NEFA)IBA
01/2018 - 07/2002
3LDL Lipoproteins (beta Lipoproteins)IBA
01/2016 - 07/2002
3IDegLiraIBA
10/2015 - 11/2014
3Lipoproteins (Lipoprotein)IBA
08/2013 - 10/2007
3Biomarkers (Surrogate Marker)IBA
07/2012 - 01/2007
31,5-anhydroglucitolIBA
06/2012 - 06/2006
2Glucagon (Glukagon)FDA Link
11/2020 - 01/2017
2CanagliflozinIBA
01/2020 - 11/2018
2Proteins (Proteins, Gene)FDA Link
01/2019 - 09/2009
2EnzymesIBA
01/2019 - 01/2017

Therapy/Procedure

58Therapeutics
11/2022 - 01/2004
34Glycemic Control
01/2021 - 01/2004
9Injections
01/2021 - 07/2010
6Surgical Amputation (Amputations)
10/2021 - 11/2002
2Precision Medicine
01/2022 - 06/2013
2Aftercare (After-Treatment)
01/2021 - 01/2018